Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/21/2012US20120157541 Soluble pharmaceutical formulations of n,n-diaminodiphenyl sulfone for optimal use in the treatment of various diseases
06/21/2012US20120157539 Nuclear receptor binding agents
06/21/2012US20120157538 Compounds for the Inhibition of Herpes Viruses
06/21/2012US20120157537 NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
06/21/2012US20120157536 Composition for transdermal administration of non-steroidal anti-flammatory drug
06/21/2012US20120157535 Prophylactic and/or therapeutic agent for dysmenorrhea
06/21/2012US20120157534 Compositions and methods of treatment for inflammatory diseases
06/21/2012US20120157533 Magnesium Compositions and Uses Thereof for Metabolic Disorders
06/21/2012US20120157532 Method Of Treating Or Preventing A Convulsive Disorder In A Patient In Need Thereof
06/21/2012US20120157531 Compositions and methods for lowering triglycerides
06/21/2012US20120157530 Methods of treating hypertriglyceridemia
06/21/2012US20120157529 Composition and Method for Prevention, Mitigation or Treatment of an Enteropathogenic Bacterial Infection
06/21/2012US20120157528 Leave-on nonsolid skin conditioning compositions containing 12-hydroxystearic acid and ethoxylated hydrogenated castor oil
06/21/2012US20120157527 Cosmetic use of a jasmonic acid derivative for treating the hair and the scalp
06/21/2012US20120157526 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
06/21/2012US20120157525 Treating eczema and/or psoriasis
06/21/2012US20120157524 3-methanesulfonylpropionitrile for treating inflammation and pain
06/21/2012US20120157523 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
06/21/2012US20120157522 B. Anthracis Prevention and Treatment: Mutant B. Anthracis Lacking Luxs Activity and Furanone Inhibition of Growth, AI-2 Quorum Sensing, and Toxin Production
06/21/2012US20120157521 Treatment of macular degeneration
06/21/2012US20120157520 Dioxanes derived from regrouping carbohydrates and c-glycosides, process for obtaining same and uses thereof
06/21/2012US20120157519 Tellerium-containing compounds for treating viral infections
06/21/2012US20120157518 Sublingual Spray Formulation Comprising Dihydroartemesinin
06/21/2012US20120157517 Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof
06/21/2012US20120157516 Novel thiophene compounds for use in therapy
06/21/2012US20120157515 Methods and compositions for the treatment of "Burning Feet Syndrome"
06/21/2012US20120157514 Oligomeric compounds and compositions for use in modulation of small non-coding rnas
06/21/2012US20120157513 Small Peptide Expression System in Mammalian Cells
06/21/2012US20120157512 Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
06/21/2012US20120157511 5' phosphate mimics
06/21/2012US20120157510 Controlling The Potential Of Primate Neural Stem Cells By Regulating Pax6
06/21/2012US20120157509 GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA
06/21/2012US20120157508 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
06/21/2012US20120157507 USP47 Inhibtors and Methods to Induce Apoptosis
06/21/2012US20120157506 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis
06/21/2012US20120157505 Oral formulations of bendamustine
06/21/2012US20120157504 New Process
06/21/2012US20120157503 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
06/21/2012US20120157502 Phenanthrenone compounds, compositions and methods
06/21/2012US20120157501 Isoketal scavengers and mitigation of disorders involving oxidative injury
06/21/2012US20120157500 Jak inhibition blocks rna interference associated toxicities
06/21/2012US20120157499 Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
06/21/2012US20120157497 Compounds having analgesic and/or immunostimulant activity
06/21/2012US20120157496 Stabilized and preserved ketotifen ophthalmic compositions
06/21/2012US20120157495 Benzimidazole derivatives
06/21/2012US20120157494 Isoindolyl compounds
06/21/2012US20120157493 Antifungal and Antiparasitic Indoloquinoline Derivatives
06/21/2012US20120157492 Antibiotic drug
06/21/2012US20120157491 Muscarinic acetylcholine receptor antagonists
06/21/2012US20120157490 N-biarylamides
06/21/2012US20120157489 Treatment of endometriosis
06/21/2012US20120157488 Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
06/21/2012US20120157487 Sulfur derivatives as chemokine receptor modulators
06/21/2012US20120157484 Tryptophan hydroxylase inhibitors
06/21/2012US20120157483 Method for Treating Liver Diseases of Various Origins
06/21/2012US20120157482 Compounds and methods
06/21/2012US20120157481 Tricyclic pyrimidine derivatives as wnt antagonists
06/21/2012US20120157480 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
06/21/2012US20120157479 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
06/21/2012US20120157477 Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
06/21/2012US20120157476 Oxime compounds
06/21/2012US20120157475 Combination Preparation Against Vertigo
06/21/2012US20120157474 Methods of Identifying and Using General or Alternative Splicing Inhibitors
06/21/2012US20120157473 Therapeutic methods and compounds
06/21/2012US20120157472 Method for treating colorectal cancer
06/21/2012US20120157471 Benzimidazole derivatives
06/21/2012US20120157470 Salts and crystalline forms of an apoptosis-inducing agent
06/21/2012US20120157469 Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
06/21/2012US20120157468 Plk inhibitor salts
06/21/2012US20120157467 Composition and use for phosphodiesterase inhibitors
06/21/2012US20120157466 Heterocyclic compounds with cxcr3 antagonist activity
06/21/2012US20120157465 Dna methylation inhibitors
06/21/2012US20120157464 Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
06/21/2012US20120157463 Chromone derivatives, a process for their preparation and their therapeutic applications
06/21/2012US20120157462 Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning
06/21/2012US20120157461 Indolyl-Substituted Pyrazino-Quinolines and Their Use for the Treatment of Cancer
06/21/2012US20120157460 Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
06/21/2012US20120157459 Novel 3-hydroxy-5-arylisothiazole derivative
06/21/2012US20120157458 Imidazotriazinone compounds
06/21/2012US20120157457 Compositions and methods for inducing neuronal differentiation
06/21/2012US20120157456 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
06/21/2012US20120157455 Compounds And Compositions For Treating Cancer
06/21/2012US20120157454 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
06/21/2012US20120157453 Raf inhibitor compounds and methods of use thereof
06/21/2012US20120157452 1h-pyrazolo[3,4-b] pyridine compounds for inhibiting raf kinase
06/21/2012US20120157451 Raf inhibitor compounds and methods of use thereof
06/21/2012US20120157450 Anhydrate Forms Of A Pyridine Derivative
06/21/2012US20120157449 Benzofurane compounds
06/21/2012US20120157448 Compounds for treating neurodegenerative diseases
06/21/2012US20120157447 Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same
06/21/2012US20120157446 Medical use
06/21/2012US20120157445 Cognitive Function
06/21/2012US20120157444 Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators
06/21/2012US20120157443 Bruton's tyrosine kinase inhibitors
06/21/2012US20120157442 Heteroaryl btk inhibitors
06/21/2012US20120157441 Inhibitors of the mutant form of kit
06/21/2012US20120157440 Novel fused pyridine compounds as casein kinase inhibitors
06/21/2012US20120157439 Raf inhibitor compounds and methods of use thereof
06/21/2012US20120157438 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
06/21/2012US20120157437 Vla-4 inhibitory drug
1 ... 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 ... 7860